Fortress Biotech (NASDAQ:FBIOP) Shares Down 4.7% – Should You Sell?

Shares of Fortress Biotech, Inc. (NASDAQ:FBIOPGet Free Report) were down 4.7% during mid-day trading on Friday . The company traded as low as $11.85 and last traded at $11.9040. Approximately 26,423 shares traded hands during trading, a decline of 19% from the average daily volume of 32,476 shares. The stock had previously closed at $12.49.

Fortress Biotech Price Performance

The business’s 50-day simple moving average is $9.66 and its two-hundred day simple moving average is $8.31.

Fortress Biotech Company Profile

(Get Free Report)

Fortress Biotech, Inc (NASDAQ: FBIOP) is a biopharmaceutical company that acquires, develops and commercializes innovative therapeutics for the treatment of patients with serious diseases. Operating as a biotech accelerator, Fortress Biotech partners with experienced management teams to advance products from early-stage discovery through regulatory approval and commercial launch. Its diversified portfolio spans multiple therapeutic areas, including oncology, rare diseases, dermatology, ophthalmology and neuromuscular disorders.

The company’s business model centers on establishing and funding product-centric subsidiary companies, each focused on a specific drug candidate or therapy.

Recommended Stories

Receive News & Ratings for Fortress Biotech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fortress Biotech and related companies with MarketBeat.com's FREE daily email newsletter.